J
Jacques Gaudreault
Researcher at Genentech
Publications - 20
Citations - 1528
Jacques Gaudreault is an academic researcher from Genentech. The author has contributed to research in topics: Ranibizumab & Bevacizumab. The author has an hindex of 12, co-authored 20 publications receiving 1456 citations. Previous affiliations of Jacques Gaudreault include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
TL;DR: In this paper, the authors evaluated the pharmacokinetic and serum bioavailability of ranibizumab after a single intravitreal (ITV) or intravenous (IV) dose in cynomolgus monkeys.
Journal ArticleDOI
Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
Jian-Feng Lu,Rene Bruno,Steve Eppler,William Novotny,Bert L. Lum,Jacques Gaudreault,Jacques Gaudreault +6 more
TL;DR: Simulations showed that similar steady-state exposures can be maintained when the weekly mg/kg dose rate is maintained, therefore allowing administration of bevacizumab to coincide with the frequency of administration of the cytotoxic agents.
Journal ArticleDOI
Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Jacques Gaudreault,David Tai Wai Fei,Joseph C. Beyer,Anne M. Ryan,Linda Rangell,Vanessa Shiu,Lisa A. Damico +6 more
TL;DR: It is demonstrated that following ITV injection, ranibizumab has a vitreous half-life of 2.9 days with minimal systemic exposure, supporting its clinical development for neovascular AMD.
Journal ArticleDOI
Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
John B. Lowe,James Araujo,Jihong Yang,Mike Reich,Amy Oldendorp,Vanessa Shiu,Valerie Quarmby,Henry B. Lowman,Samantha Lien,Jacques Gaudreault,Mauricio Maia +10 more
TL;DR: Results show that ranibizumab is capable of binding to and specifically inhibiting the activities of 3 biologically active forms of VEGF-A, which supports its clinical utility in the treatment of neovascular AMD.
Journal ArticleDOI
Design, Construction, and In Vitro Analyses of Multivalent Antibodies
Kathy D. Miller,Gloria Meng,Jun Liu,Amy Hurst,Vanessa Hsei,Wai Lee Wong,Rene Ekert,David A. Lawrence,Steven Sherwood,Laura DeForge,Jacques Gaudreault,Gilbert A. Keller,Mark X. Sliwkowski,Avi Ashkenazi,Leonard G. Presta +14 more
TL;DR: In this paper, the authors designed and generated multivalent human IgG Ab forms with tandem Fab repeats with the aim of mimicking cross-linked Abs to improve the therapeutic potency of these types of Abs.